M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Immunomedics Inc's solid tumour antibody-drug conjugate programmes now in Phase II clinical trials
Biopharmaceutical company Immunomedics Inc (NasdaqGM:IMMU) stated on Monday that three Phase I trials evaluating its antibody-drug conjugates (ADCs), IMMU-130 and IMMU-132, have now entered Phase II clinical trials.
The company said IMMU-130 (labetuzumab-SN-38) was being studied in two...
If you want to view the full text, you must first purchase archive credits.
Return to Archives